Overall verdict
Sell
2.7/10
1-year performance
-59.00%
Score breakdown
Down 59.0% over 1 year, 5% of the 52-week range.
Strongest: Growth 10.0/10. Weakest: Shareholder return 0.0/10.
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
Donn Casale
Founded
2015
Employees
163
Revenue / employee
517 043 USD
Next earnings
March 9, 2027 (estimated)
Institutional holders
- BlackRock, Inc.5.55%
- STATE STREET CORP3.67%
- GEODE CAPITAL MANAGEMENT, LLC1.59%
- MORGAN STANLEY0.37%
- GOLDMAN SACHS GROUP INC0.32%
- RENAISSANCE TECHNOLOGIES LLC0.17%
- Bank of New York Mellon Corp0.17%
- JPMORGAN CHASE & CO0.04%
- FMR LLC0.01%
- Rest of the register88.10%
9 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
13.15 USD
52-week low
2.44 USD
1-year performance
-59.00%
Declining
Year-to-date performance
-74.59%
Declining
Drawdown
-77.49%
Major drawdown
Position in the 52-week range
5% of range
Gross margin 71.0%, the company loses 163.6% of its revenue, ROIC -112.7%, ROE -294.6%.
Net margin
-163.64%
Negative
Sector -214.18%|S&P 13.35%
Gross margin
71.03%
Exceptional
Return on equity (ROE)
-294.57%
Negative
Sector -55.30%|S&P 16.98%
Return on invested capital (ROIC)
-112.70%
Negative
Free cash flow margin (FCF)
-149.89%
Negative
Margin stability
72173.3 pts
Very uneven
Revenue to net income
Growth
10.0/10Revenue up 16.0% over 1 year.
Revenue (trailing 12 months)
122M USD
Revenue growth (1y)
16.03%
Hyper-growth
Revenue growth (3y)
6304.10%
Hyper-growth
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.0x|S&P 22.1x
Forward P/E (adjusted)
—
N/A (loss)
EV / EBITDA
—
N/A (loss)
Sector 16.5x|S&P 14.9x
PEG
—
Sector 0.87|S&P 0.84
Market cap
298M USD
Financial strength
6.9/10Cash covers 113.6% of the debt, net debt/EBITDA -0.5x.
Net debt / EBITDA
-0.5x
Very solid
Gearing (net debt / equity)
—
Cash
138M USD
Cash / market cap
46.50%
Very solid
Cash / total debt
113.58%
Net cash
Interest coverage
-69.0x
Stretched
Net debt
-16.5M USD
Equity
-12.0M USD
Closed daily candles, 2 years
Last close on November 20, 2026: 2.96 USD
- MM203.43
- MM503.90
- MM2006.87
- RSI 1436.9
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-9.96%
200-day average slope, 3 months
-20.91%
50-day average slope, 1 month
-19.57%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
7.43 % per day
Volatility change
+54.75%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -1.89 (4) | -1.91 (3) | 120 (4) | — | -188 (4) |
| 2027 | -0.78 (4) | -0.82 (3) | 165 (4) | — | -80 (4) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 7, 2026.
Same sub-industry: 797 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ALERS | 4.5 | 4.5 | 284M USD | 36.9x | 4.2 % | 9.1 % | 3.7 % | -0.1x | 2.0 % | 8.2 % | ||
| 2 | BNTC | 4.0 | N/A | 286M USD | Not meaningful (loss) | — | — | -37.5 % | 3.2x | -6.2 % | -40.5 % | ||
| 3 | SPRY | 2.7 | 3.0 | 298M USD | Not meaningful (loss) | -163.6 % | 16.0 % | -112.7 % | -0.5x | -61.5 % | -59.0 % | ||
| 4 | 7630 | 2.7 | 2.7 | 292M USD | Not meaningful (loss) | -213.6 % | 14.1 % | -60.5 % | 5.4x | -4.8 % | -77.2 % | ||
| 5 | 4894 | 2.1 | 1.5 | 296M USD | Not meaningful (loss) | -1478.4 % | -52.6 % | -15.8 % | 5.0x | — | -13.8 % | ||
| 6 | EVMN | 2.1 | 0.9 | 291M USD | Not meaningful (loss) | — | -100.0 % | -68.1 % | 1.3x | -31.3 % | -63.4 % | ||
| 7 | 6945 | 1.5 | N/A | 287M USD | Not meaningful (loss) | — | — | -22.4 % | 4.5x | -4.1 % | -7.9 % | ||
| 8 | GLSI | 1.5 | N/A | 283M USD | Not meaningful (loss) | — | — | -10656.2 % | 0.3x | -4.5 % | 134.2 % | ||
| 9 | 2617 | 1.5 | N/A | 294M USD | Not meaningful (loss) | -738.1 % | — | -36.0 % | 3.6x | -12.3 % | -96.8 % |
